Anti-myelin-associated glycoprotein associated polyneuropathy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:30:37 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Anti-myelin-associated glycoprotein associated polyneuropathy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Zanubrutinib and Rituximab for Patients with IgM Monoclonal Gammopathy and MAG Antibodies-Related Polyneuropathy https://clinicaltrials.eu/trial/study-on-zanubrutinib-and-rituximab-for-patients-with-igm-monoclonal-gammopathy-and-mag-antibodies-related-polyneuropathy/ Wed, 29 Apr 2026 14:26:23 +0000 https://clinicaltrials.eu/trial/study-on-zanubrutinib-and-rituximab-for-patients-with-igm-monoclonal-gammopathy-and-mag-antibodies-related-polyneuropathy/ This clinical trial is focused on studying a condition known as IgM monoclonal gammopathy of unknown significance (MGUS) and its related nerve disorder, myelin associated glycoprotein (MAG) antibodies associated polyneuropathy. These conditions can affect the nerves, leading to symptoms like weakness and numbness. The study is exploring the use of a medication called Zanubrutinib, which is taken as a hard capsule, in combination with another treatment called Rituximab. The aim is to see if this combination can improve nerve function in patients over a period of 12 months.

Participants in the study will receive the treatment and be monitored for any changes in their condition. The study will last for up to 36 months, during which time the safety and tolerability of the treatment will also be assessed. The researchers are interested in understanding how well patients adhere to the treatment and any side effects that may occur. The study will also track improvements in the ability to perform daily activities and overall quality of life.

The trial will measure various outcomes, including changes in nerve function and overall health, using specific scoring systems designed to assess disability and quality of life. The study will also look at how the treatment affects certain blood markers and the presence of specific antibodies. This research aims to provide valuable insights into the potential benefits of Zanubrutinib and Rituximab for patients with these nerve-related conditions.

]]> Study of Rituximab compared to placebo in patients with anti-MAG neuropathy who are likely to respond well to treatment https://clinicaltrials.eu/trial/study-on-rituximab-for-patients-with-anti-mag-neuropathy-who-are-likely-to-respond-well/ Wed, 29 Apr 2026 14:22:39 +0000 https://clinicaltrials.eu/trial/study-on-rituximab-for-patients-with-anti-mag-neuropathy-who-are-likely-to-respond-well/ This study focuses on patients with anti-MAG neuropathy, a rare nerve condition that causes weakness and numbness in the arms and legs. The condition is associated with the presence of specific antibodies that damage the protective covering of nerves. The study will test the effectiveness of rituximab, a medication that targets certain immune system cells, compared to placebo in treating this condition.

The purpose of this research is to determine if rituximab can improve neurological function in people with anti-MAG neuropathy who are likely to respond well to the treatment. The study will last 12 months, during which participants will receive either rituximab or placebo through intravenous infusion. The treatment will be given along with sodium chloride solution, which helps deliver the medication into the bloodstream.

Throughout the study, doctors will monitor changes in participants’ nerve function and ability to perform daily activities. They will assess walking ability, hand function, and nerve signals to evaluate how well the treatment is working. The study will also track the levels of harmful antibodies in the blood and any side effects that may occur during treatment.

]]>